Close Menu

NEW YORK – Invitae announced on Sunday preliminary 2019 revenues of around $216 million, representing 45 percent growth over $147.7 million the prior year but falling short of the consensus Wall Street estimate of $219.9 million and short of its own annual revenue projections of $220 million.  

The company said testing volume grew 60 percent year over year to more than 482,000 samples compared to 303,000 samples in 2018. The company had previously projected that it would accession more than 500,000 samples in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.